Verrica, a Dermatology Therapeutics Company, Announced the Pricing of Public Offering of Common Stock

On June 29, 2022,- Verrica Pharmaceuticals Inc., a dermatology therapeutics company that develops medicines for skin diseases needing medical interventions, declared the pricing of the underwritten public offering of its common stock of 12,000,000 shares at a rate of $2.10 per share to the public. Also, Verricagranted a 30-day option to purchase up to 1,800,000 additional shares of common stock at the public offering price. The gross incomes from the offering to Verrica are likely to be around $25.2 million, before subtracting underwriting commissions discounts and offering expenses, but exclusive of any exercise of the underwriter’s option. The offering is anticipated to close on July 5, 2022, depending upon the customary closing conditions.

RBC Capital Markets is the sole book-runner for this offering.

A shelf registration statement regarding the offering was registered on March 13, 2020, with the Securities and Exchange Commission and declared operative by the SEC on March 25, 2020. An introductory prospectus supplement and supplementary prospectus relating to the offering have been filed with the SEC and are accessible on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When obtainable, copies of the concluding prospectus supplement and the accompanying prospectus would also be attained by RBC Capital Markets.